Boron-Containing heterocycles as promising pharmacological agents. 2022

Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA; Department of Medicine and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: Bhaskar.Das@liu.edu.

The incorporation of the "magic" boron atom has been established as an important new strategy in the field of medicinal chemistry as boron compounds have been shown to form various bonds with their biological targets. Currently, a number of boron-based drugs (e.g. bortezomib, crisaborole, and tavaborole) have been FDA approved and are in the clinic, and several other boron-containing compounds are in clinical trials. Boron-based heterocycles have an incredible potential in the ongoing quest for new therapeutic agents owing to their plethora of biological activities and useful pharmacokinetic profiles. The present perspective is intended to review the pharmacological applications of boron-based heterocycles that have been published. We have classified these compounds into groups exhibiting shared pharmacological activities and discussed their corresponding biological targets focusing mainly on the most potent therapeutic compounds.

UI MeSH Term Description Entries
D001895 Boron A trace element with the atomic symbol B, atomic number 5, and atomic weight [10.806; 10.821]. Boron-10, an isotope of boron, is used as a neutron absorber in BORON NEUTRON CAPTURE THERAPY. Boron-11,Boron 11
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341

Related Publications

Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
May 2024, Molecules (Basel, Switzerland),
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
December 2023, International journal of molecular sciences,
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
February 2022, ACS omega,
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
January 2020, Anti-cancer agents in medicinal chemistry,
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
July 2019, Chemical Society reviews,
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
April 2022, Molecules (Basel, Switzerland),
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
February 2023, Pharmaceuticals (Basel, Switzerland),
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
May 2010, Anti-cancer agents in medicinal chemistry,
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
June 2018, Archiv der Pharmazie,
Bhaskar C Das, and Mohammed Adil Shareef, and Sasmita Das, and Nitesh K Nandwana, and Yogarupa Das, and Mariko Saito, and Louis M Weiss
January 2022, Life (Basel, Switzerland),
Copied contents to your clipboard!